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Natural history of nodding syndrome
Nodding syndrome (NS) is a poorly understood acquired neurological disorder affecting previously normally developing children in geographicallybound regions in sub-Saharan Africa. Northern Uganda, Southern Tanzania and South Sudan have the highest burden of disease. There are an estimated 10,000 cases in these three countries (CDC, 2012; Idro et al., 2014; Landis et al., 2014) . Recently, there have also been reports of similar patients in The Democratic Republic of Congo and the Central African Republic (Robert Colebunders, personal communication) . In the affected districts of northern Uganda, the prevalence of nodding syndrome among the affected age group is 6.8 (95% CI: 5.9-7.7) per 1,000 (Iyengar et al., 2014) . The aetiology is unclear (Spencer et al., 2013) but there has been a consistent epidemiological association with infection with the filarial worm, Onchocerca volvulus (Kaiser et al., 1996; Ngugi et al., 2013; Colebunders et al., 2015) . Recent pilot studies suggest that nodding syndrome may be a neuroinflammatory disorder with antibodies to Onchocerca volvulus-specific proteins cross-reacting with host proteins (Idro et al., 2016; Johnson et al., 2017) . Definitive studies to confirm these findings are ongoing. Affected individuals develop symptoms between the ages of three and 18 years and present with a distinct feature, head nodding. Head nodding is characterised by repeated vertical drops of the head onto the chest, 5-20 times/minute, at the sight of food, spontaneously or in association with cold weather (Edwards, 2012; Wamala et al., 2015) . The head nods have been characterised as atonic seizures (Sejvar et al., 2013) but in many children are associated with myoclonic jerks and/or atypical absence seizures. Progressively, patients develop convulsive seizures, behaviour difficulties and psychiatric disorders, declining cognitive function, wasting and growth failure, delayed development of secondary sexual characteristics, and physical and motor disability (Idro et al., 2013a) . Diagnostic EEGs show generalized slow-wave activity with or without interictal epileptiform discharges. The brain MRI shows varying degrees of cortical and cerebellar atrophy and hippocampal changes in a minority (Idro et al., 2013a; Van Bemmel et al., 2014) . The natural history of nodding syndrome is inadequately described (Idro et al., 2013b; Winkler et al., 2014) . To date, there are no specifically designed prospective studies. There is no biological diagnostic test and the early symptoms that may help guide on prompt recognition are unknown. Potentially, description of these early features will facilitate prompt initiation and implementation of interventions to arrest progression. In an earlier cases series of 22 untreated patients, we proposed that the symptoms and complications of nodding syndrome probably develop over five clinical stages but this observation is yet to be confirmed (Idro et al., 2013a) . This study aimed to describe the natural history of nodding syndrome, the early features, and the progressive development of symptoms and complications of the disease. We also sought to examine if the symptoms and complications progressively clustered in the five proposed stages and if so, whether these stages were distinct enough to allow recognition.
Materials and methods
Study design
This study was part of a larger epidemiologic study of nodding syndrome in Uganda. For this study, between October and November 2013, we conducted a crosssectional survey of a retrospective cohort of patients in Pader district, obtained detailed history of the progressive development of symptoms, and performed clinical testing to describe the functional state, co-morbidities, and complications of the disease.
Setting
Northern Uganda has only recently recovered from the devastating effects of the Lord's Resistance Army insurgency against the Government of Uganda. The region has high levels of poverty, high malaria transmission (Okello et al., 2006) and is endemic for Onchocerca volvulus (Oguttu et al., 2014; World Health Organization, 2017) . The study was conducted in Pader; the district with the highest burden of nodding syndrome. Of the over 3,000 registered patients in the country in the year 2013, about 1,200 lived in Pader. Other affected districts included Kitgum, Lamwo, Gulu, Amuru, Oyam and Lira.
Participants
A case of nodding syndrome was defined according to the World Health Organization criteria (2012) (World Health Organization, 2012) as: -a child or adolescent with head nodding on two or more occasions; -symptom onset between the ages of three and 18 years; -head nodding occurring at a frequency of 5-20/minute and in whom head nodding has been observed by a trained health worker or documented on EEG/EMG; -plus, any one of:
• Triggered by food or cold weather;
• Presence of other seizure types, other neurological abnormalities, or decline in cognitive function and;
• Clustering of cases in space (on a population basis) or time.
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Epileptic Disord, Vol. 20, No. 6, December 2018 R. Idro, et al. All suspected cases had been registered by the local Village Health Worker and at the local health centre and had only recently been initiated on symptomatic treatments at the nodding syndrome treatment centres in the district (Idro et al., 2016) . These symptomatic treatments included provision of sodium valproate, plus nutritional, physical, and psychological therapy (Idro et al., 2013b) .
Ethical approval and informed consent procedures
Ethical approval for the study was obtained from Makerere University School of Medicine Research and Ethics Committee. Written informed consent was obtained from parents or the primary caregiver if the parent was unavailable. Because of challenges of severe cognitive impairment in some children, no formal assent was obtained in most age-appropriate children. This requirement had been waived by the ethics committee.
Recruitment
Participants were recruited from two highly affected sub-counties in Pader district: Atanga and Awere. These two were purposively chosen because of the large number of patients and close geographical location. In each sub-county, only the most affected villages, with at least five probable patients, were selected. A total of 11 villages were included. All probable nodding syndrome patients in each selected village were invited to participate.
Data collection
The study was conducted by a large multidisciplinary team comprised of clinicians, nurses, therapists, psychologists, and a social worker. Each village was allocated a day and in villages with many patients, up two days. Participants were informed about the study at least two weeks earlier and were assessed at any of the village meeting places, the home of the village chair, or the local health centre. Two days before the survey, the study nurses went back to the villages and reminded the village health workers and parents about the study. On the morning of the survey, the village health worker helped gather parents and the patients at the agreed place. Patients who could not move were assessed in their homes. A joint general discussion was held on study procedures with all parents, and prospective participants followed by individual written consent. Specifically developed case record forms were administered to consenting parents/patients and used to carefully document the history of each patient. This included history of the pregnancy, birth and early development, the past medical history, timing of the onset of head nodding, and clinical features prior to this. Symptoms after the onset of head nodding were then documented on a timeline together with the intervals up to the onset. The type, frequency, and severity of seizures, treatments received, schooling, visual, hearing and cognitive difficulties, ability to perform age-appropriate activities of daily living, and independence in self-care were all documented. A full physical examination, standard neurological testing, and functional assessment of the patients were then performed. Motor function was assessed using the Gross Motor Classification System (McDowell, 2008) while the Strengths and Difficulties Questionnaire (SDQ) (Goodman, 1997 ) was used to screen for behavioural difficulties. Children screening positive for behavioural difficulties on the SDQ had psychiatric assessments using specific domains of the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI KID) (Sheehan et al., 2010) .
Data and statistical analysis
Completed Case Record Forms were double entered into a Microsoft Access database and exported to STATA (Version 13.0, College Station, TX). The time at onset of head nodding was defined as the time the parent or primary caregiver first noticed head nodding in the participant. To delineate the stages, the timing of the symptoms and development of the complications were all related to the onset of head nodding. To establish clustering of symptoms within a time range, the lower and upper quartiles were used. For each symptom, the median, lower (25%), and upper (75%) quartile time at onset of the symptoms, either prior to or after the onset of head nodding, was determined. Symptoms with similar values of the 25% and 75% quartiles were taken to cluster together.
Results
General description
Altogether, there were 243 patients with suspected nodding syndrome registered in the 11 villages surveyed. Four were unavailable (three travelled to different relations and one was attending school in another village) at the time of the study and so, were not assessed. On screening, 16 children were found to have been misdiagnosed with nodding syndrome. They had other forms of epilepsy and were excluded. Thirteen other children, who had data on demographic characteristics but were missing information for several other variables, were also excluded. The remaining
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A u t h o r O f f p r i n t 210 children were available for the study. There were no sex differences; just over half were male. The mean age at the onset of head nodding was 7.5 (SD: 3.0) years and the mean duration with head nodding at the time of the survey was 6.2 (SD: 2.7) years. The majority of patients, 163/210 (77.6%), developed head nodding after the age of five years.
The prodromal or early features of nodding syndrome
The early or prodromal features of nodding syndrome were defined as symptoms that developed before the onset of head nodding. These included what parents and primary caregivers described as periods of staring blankly or being inattentive, complaints of dizziness, excessive sleepiness, lethargy, and general body weakness (table 1) . One hundred and thirty participants (61.9%) reported at least one of these symptoms. Overall, the features developed between two weeks and 24 months before the onset of head nodding. Of the group, excessive sleepiness and general body weakness were the most common (17.1%), followed by dizziness (16.2%). Using the 25% and 75% quartiles of the time at onset, lethargy (median time: 10 months before onset of head nodding), general body weakness, and decline in comprehension (median time: 2.5 months before onset of head nodding) were the earliest symptoms to develop. Dizziness with periods of staring blankly and being inattentive, with a median period of a month before the onset of head nodding, were the last prodromal features to develop ( figure 1) . No EEGs or brain imaging of patients at this stage were obtained.
The head nodding stage
Head nodding is the pathognomonic feature of the syndrome. In the initial stages, the head nods were reported mostly in the early hours of the morning but also while eating food and with a cold bath or breeze. The head would drop forward repeatedly at a characteristic frequency of 5-20 Hz initially for brief moments, but with time, the episodes lasted several minutes. Earlier EEG studies showed that these head nods are atonic seizures, but some patients also have concurrent myoclonic jerks and atypical absences. Initially, the patients maintained awareness but again with time, they would stare blankly, drool, and then progress to develop other seizure types including tonic-clonic and myoclonic seizures. With continued disease progression and the development of other types of seizures, the head nodding seized in some patients.
Features developing after the onset of head nodding
After the onset of head nodding, almost all progressively developed other features ( Convulsive (focal, generalized tonic-clonic and myoclonic jerks) and non-convulsive seizures (absences) in 62.4% were the other leading features to develop. Behavioural difficulties and psychiatric disorders included aggression, hyperactivity, auditory and visual hallucinations, and clinical depression. Progressively, some patients developed physical disability and deformities of the limbs; deformities around the knees and ankles, flat feet and hands, and deformities of the chest and spine (pectus deformities, kyphosis, and scoliosis). Severe disability with inability to walk was less frequently reported (table 2) . A timeline of these symptoms is also shown in figure 1 . Symptoms reported by less than 10 children (<5%) were not included in the time line.
Discussion
This study aimed to describe the natural history of nodding syndrome and in particular, the early features and the progressive development of symptoms and complications. It also examined if symptoms and complications clustered as proposed earlier, in five stages. The study found that the features of untreated nodding syndrome progressively develop across five overlapping stages over several years. Head nodding (the head nodding stage) is preceded by a prodromal period in at least two thirds of patients. However, unlike what was reported in the earlier small case series (Idro et al., 2013a) , the prodromal period has a variable length of up to two years. Although nonspecific and easily confused with other conditions ( intensity of convulsive seizures, as well as cognitive and emotional dysfunction; the convulsive seizure stage. Progressively, there are multiple functional impairments in behaviour and motor abilities. Some also develop deficits in speech, vision or hearing while others develop overt psychiatric disorders. Beyond this period, deformities of the limbs, chest, and spine, faltering growth or failure of growth are observed. Some become bedridden; the severe disability stage. However, not all patients progress to these advanced stages and in many cases, marked improvement and reversal of symptoms have been observed with antiepileptic drug treatment and rehabilitation (Idro et al., 2014) . The wide spectrum of clinical signs involving multiple systems including the central nervous system, motor, and endocrine systems would in addition also suggest that nodding syndrome is a multisystem disease rather than a purely neurological disorder and emphasise the need for a multidisciplinary investigation of the aetiology and care provision. Stage Five: Severe disability with limited independent mobility (the general picture is that of a severely wasted child with apathy and depressive features including a flat affect, poor appetite, and limited speech.)
The continued decline in the burden of seizures in individual patients with antiepileptic therapy compared to reports at the height of the epidemic points to the success and importance of antiepileptic treatment in these patients. In addition, the lower number of patients in advanced stages of the disease in Uganda today may imply halting of disease progression in some patients and possibly a reversal in poor health with application of the symptomatic treatments. Overall, the timing of the progression of symptoms in this study correlates well with that described in the earlier proposed clinical stages (Idro et al., 2013a) . However, the stages are not so distinct and overlap.
Beyond the prodromal and the head nodding stages, patients developed convulsive seizures within one to three years, cognitive dysfunction within one to four years, and psychiatric disorders and motor difficulties overlapped within two to five years before onset of severe disability at between three and six years ( figure 1, tables 2, 4) . Prospective studies of incident cases may more conclusively demonstrate the respective stages. With emerging reports of nodding syndrome now in the Democratic Republic of Congo and the Central African Republic, together with the growing problem in South Sudan, the need to clearly understand the pathogenesis of this disorder and develop specific treatment and preventive interventions cannot be stronger. Furthermore, the multisystem nature of the disease demonstrated here should also be explored. The variable progression of the disease may provide some clues. In the meantime, in the absence of a specific treatment, the symptomatic treatment protocol that has been implemented in Uganda with some success could be adopted in the neighbouring countries. The primary limitation of this study was the use of a retrospective cohort and the challenges of recall in using parental history to describe the natural history of the disease. Again, a prospective study would be ideal but since 2014, there have been no incident cases of nodding syndrome in Uganda. Prospective studies may now only be possible in the new areas reporting the disease. Despite this limitation, highly skilled clinicians screened the participants and used standardised forms adapted from the previous case series to obtain the progressive development of symptoms. Secondly, there is no specific biological marker or diagnostic test for nodding syndrome. It was therefore not possible to correlate the clinical stages to plasma or cerebrospinal fluid levels of a specific marker. We also did not specifically obtain any functional (e.g. EEG) or structural imaging of the brain in the prodromal stage nor in the progressive stages to correlate with the specific clinical observations. However, recent documentation of cross-reacting antibodies in some patients with nodding syndrome, which pathologically link Onchocerca volvulus infection to nodding syndrome, is starting to provide an insight into the possible cause of the disease, may explain disease progression, and may, in the not-so-far future, provide biological markers that may correlate with clinical observations. Stage-specific EEG and brain MRI features will be valuable additions in future studies. If indeed nodding syndrome is a neuroinflammatory disorder, as proposed, with antibodies to Onchocerca volvulus antigens that cross-react with host proteins, the slow progression of the disease described here -over several years -would suggest that this is really an insidious process.
In conclusion, nodding syndrome is probably a multisystem disorder in which symptoms develop over several overlapping and progressively severe stages, starting with a non-specific prodromal period of variable length. A high index of suspicion and prompt recognition of especially the early features may guide in the early identification of at-risk patients and promote the prompt initiation of interventions before extensive brain injury develops. The wide spectrum of symptoms and complications emphasises the need for multi-disciplinary care. In addition to advancing our understanding of nodding syndrome, the clinical stages identified here will also be helpful in the development and ascertainment of end points in intervention studies.
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